Sopisa Benjakul

Sopisa Benjakul

Auto-generated profile, based on publicly available information

Sopisa Benjakul

Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
EVEline Benno Vaage
Eline Benno Vaage
MBMalin Bern
Malin Bern
SBSopisa Benjakul
Sopisa Benjakul
JAJan Terje Andersen
Jan Terje Andersen
Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.

1 August 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
CACláudia Azevedo
Cláudia Azevedo
SPSoraia Pinto
Soraia Pinto
SBSopisa Benjakul
Sopisa Benjakul
JNJeannette Nilsen
Jeannette Nilsen
HSHélder A. Santos
Hélder A. Santos
Bruno SarmentoBruno Sarmento
Bruno Sarmento

26 May 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
JNJeannette Nilsen
Jeannette Nilsen
KAKristin Hovden Aaen
Kristin Hovden Aaen
SBSopisa Benjakul
Sopisa Benjakul
FRFulgencio Ruso-Julve
Fulgencio Ruso-Julve
TGThomas Uwe Greiner
Thomas Uwe Greiner
JAJan Terje Andersen
Jan Terje Andersen
Albumin has a long plasma half-life due to engagement of the neonatal Fc receptor (FcRn), which prevents intracellular degradation. However, its C-terminal end can be cleaved by carboxypeptidase A, and removal of the last leucine residue (L585) weakens receptor binding, reducing its half-life from 20 days to 3.5 days in humans. This biology has so far been overlooked when designing human albumin-fused biologics. Thus, there is a need for an engineering strategy to secure favorable FcRn binding and pharmacokinetic properties. Here, we show that a branched aliphatic amino acid or methionine at position 585 of albumin is required for optimal receptor binding, which cannot be replaced to prevent enzymatic cleavage without negatively affecting FcRn engagement. As a solution, we report that C-terminally cleaved albumin can be efficiently rescued from intracellular degradation by introducing amino acid substitutions that improve FcRn binding. This albumin-engineering strategy was also effective when applied with a therapeutic fusion partner, glucagon-like peptide 1 (GLP-1), resulting in a 2-fold increase in plasma half-life and prolonged efficacy in human FcRn transgenic mice. We demonstrate how human albumin fusions should be tailored to ensure a long plasma half-life and enhanced efficacy of fused biologics, despite potential C-terminal cleavage in vivo.

28 November 2023 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
SBSopisa Benjakul
Sopisa Benjakul
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
MVMarina Vaysburd
Marina Vaysburd
HLHeidrun Elisabeth Lode
Heidrun Elisabeth Lode
JAJan Terje Andersen
Jan Terje Andersen
Immunocompromised patients often fail to raise protective vaccine-induced immunity against the global emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Although monoclonal antibodies have been authorized for clinical use, most have lost their ability to potently neutralize the evolving Omicron subvariants. Thus, there is an urgent need for treatment strategies that can provide protection against these and emerging SARS-CoV-2 variants to prevent the development of severe coronavirus disease 2019. Here, we report on the design and characterization of a long-acting viral entry-blocking angiotensin-converting enzyme 2 (ACE2) dimeric fusion molecule. Specifically, a soluble truncated human dimeric ACE2 variant, engineered for improved binding to the receptor-binding domain of SARS-CoV-2, was fused with human albumin tailored for favorable engagement of the neonatal fragment crystallizable receptor (FcRn), which resulted in enhanced plasma half-life and allowed for needle-free transmucosal delivery upon nasal administration in human FcRn-expressing transgenic mice. Importantly, the dimeric ACE2-fused albumin demonstrated potent neutralization of SARS-CoV-2 immune escape variants.

29 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKristin Hovden Aaen
Kristin Hovden Aaen
MTMaria Francesca Testa
Maria Francesca Testa
JNJeannette Nilsen
Jeannette Nilsen
RTRebecca Tarantino
Rebecca Tarantino
CCCesare Canepari
Cesare Canepari
JAJan Terje Andersen
Jan Terje Andersen
The efficacy of hemophilia B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although FIX bound to extravascular type IV collagen (Col4) also contributes to efficient hemostasis. Here, we investigated the impact of engineering FIX for improved (K5R) or reduced (K5A) Col4 binding on the pharmacokinetic properties of FIX Padua, fused to human serum albumin (HSAQMP) engineered for favorable neonatal Fc receptor (FcRn) engagement. Hyperactive features and extended plasma half-life in human FcRn expressing mice, attributed to FIX Padua and HSAQMP engineering, respectively, was confirmed. In HB mice, PaduaKA-HSAQMP exhibited negligible extravascular distribution and the highest plasma levels at early time points followed by the steepest decay. Conversely, PaduaKR-HSAQMP showed increased extravascular distribution and a 3-fold longer functional half-life (80 hours). These findings support the use of PaduaKA-HSAQMP and PaduaKR-HSAQMP as hyperactive short- or long-term therapeutics, respectively, with opportunities for tailored HB replacement therapy.

14 August 2026 in Science Immunology
Verified
Journal Article
Closed access
JNJeannette Nilsen
Jeannette Nilsen
KSKine M. K. Sand
Kine M. K. Sand
Hana Al KhabbazHana Al Khabbaz
Hana Al Khabbaz
LLLennart Maximilian van Ligtenberg
Lennart Maximilian van Ligtenberg
SMSimone Mester
Simone Mester
JAJan Terje Andersen
Jan Terje Andersen
Immunoglobulin G (IgG)–based monoclonal antibodies are effective therapies for cancer, autoimmune diseases, and migraine. However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy. Using mouse models and an ex vivo human placental perfusion system, we show that although FcRn binds albumin independently of IgG, albumin is not transported to the fetus in mice or across human placental tissue. Fusion of IgG to albumin markedly reduced transplacental transport in both models while preserving the prolonged plasma half-life conferred by FcRn. Similarly, fragment antigen–binding fragments fused to engineered albumin with enhanced FcRn binding showed minimal fetal exposure. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, albumin fusion of an anti–human platelet antigen IgG reduced fetal antibody transfer and attenuated thrombocytopenia in the offspring. These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.